secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2026-09-01T22:23:31+00:00
Accession:  0001193125-26-378838
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma prices $50.8M public offering of common stock and warrants
---------------------------------------------------------------------

- Priced offering of 22,055,000 shares and pre-funded warrants for 19,900,000 shares, each with accompanying warrants for 41,955,000 shares total.
- Combined offering price $1.21 per share/warrant; gross proceeds ~$50.8M, net ~$47.0M.
- Proceeds to fund late-stage development, regulatory submission, and commercialization prep for rezatapopt.
- Warrants exercisable immediately, expire in 5 years; exercise price resets to 33% of initial upon FDA acceptance of rezatapopt NDA.
- Offering expected to close September 2, 2026; TD Cowen sole book-runner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312526378838/0001193125-26-378838-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312526378838/d113784d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-378838

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer